Arias Luis, Ruiz-Moreno Jose M, Gómez-Ulla Francisco, Fernández Maribel, Montero Javier
Department of Ophthalmology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
Retina. 2009 Nov-Dec;29(10):1444-9. doi: 10.1097/IAE.0b013e3181ae712d.
To assess efficacy and safety in the treatment of nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration with intravitreal ranibizumab.
Retrospective, multicentric, noncomparative, interventional case series. We included patients with naïve extrafoveal and juxtafoveal choroidal neovascularization treated with intravitreal ranibizumab and a follow-up of 1 year. Patients were evaluated using visual acuity testing with Snellen charts, fluorescein angiography, and optical coherence tomography scans.
There were 15 patients with a mean age of 72.4 years (SD, 7.2). There were 11 juxtafoveal lesions (73.3%) and 4 extrafoveal lesions (26.6%). Eight lesions were predominantly classic (53.3%), 6 lesions were occult (40%), and 1 lesion was minimally classic (6.6%). The mean visual acuity improved from 20/60 (mean logarithm of the minimum angle of resolution = 0.47) at baseline to 20/40 (mean logarithm of the minimum angle of resolution = 0.34) at the 1-year follow-up visit (P = 0.03). The mean foveal thickness improved from 312 microm to 262 microm (P = 0.01), and the mean lesion size (disk areas) improved from 1.9 to 1.1 (P = 0.01). No cases progressed to a subfoveal location. The mean number of injections was 3.8. As complications, we had an endophthalmitis and a macular hole.
In our study, intravitreal ranibizumab showed efficacy for the treatment of nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration mainly in terms of preventing subfoveal progression.
评估玻璃体内注射雷珠单抗治疗年龄相关性黄斑变性继发的非中心凹下脉络膜新生血管的疗效和安全性。
回顾性、多中心、非对照、干预性病例系列研究。纳入初治的中心凹旁和中心凹外脉络膜新生血管患者，给予玻璃体内注射雷珠单抗，并随访1年。使用Snellen视力表、荧光素血管造影和光学相干断层扫描对患者进行评估。
共15例患者，平均年龄72.4岁（标准差7.2）。其中中心凹旁病变11例（73.3%），中心凹外病变4例（26.6%）。8处病变以典型性为主（53.3%），6处病变为隐匿性（40%），1处病变为轻微典型性（6.6%）。平均视力从基线时的20/60（最小分辨角平均对数=0.47）提高到1年随访时的20/40（最小分辨角平均对数=0.34）（P=0.03）。中心凹厚度平均从312微米降至262微米（P=0.01），病变平均大小（视盘面积）从1.9降至1.1（P=0.01）。无病例进展至中心凹下位置。平均注射次数为3.8次。作为并发症，出现了1例眼内炎和1例黄斑裂孔。
在我们的研究中，玻璃体内注射雷珠单抗在治疗年龄相关性黄斑变性继发的非中心凹下脉络膜新生血管方面显示出疗效，主要体现在预防中心凹下进展方面。
